{"filing":{"accession_number":"0001062993-26-005468","cik":"0001833141","ticker":"HELP","company_name":"Helus Pharma Inc.","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"form6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000106299326005468/form6k.htm"},"events":[{"id":36823,"run_id":33950,"accession_number":"0001062993-26-005468","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit discloses material clinical program advancements for a clinical-stage pharmaceutical company: topline data readout from the APPROACH Phase 3 study of HLP003 for MDD on track for Q4 2026, and progression of the HLP004 program with Phase 2 monotherapy study for GAD expected to initiate in Q1 2027. The company also highlights a strategic shift in HLP004 development from adjunctive to monotherapy approach. These are significant operational and clinical milestones that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, though the disclosure is primarily an investor presentation summary rather than a discrete event announcement.","company_name":"Helus Pharma Inc.","ticker":"HELP","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":41368,"accession_number":"0001062993-26-005468","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses material clinical program advancements for a clinical-stage pharmaceutical company: topline data readout from the APPROACH Phase 3 study of HLP003 for MDD on track for Q4 2026, and progression of the HLP004 program with Phase 2 monotherapy study for GAD expected to initiate in Q1 2027. The company also highlights a strategic shift in HLP004 development from adjunctive to monotherapy approach. These are significant operational and clinical milestones that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, though the disclosure is primarily an investor presentation summary rather than a discrete event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:47:03.998758+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41368,"accession_number":"0001062993-26-005468","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses material clinical program advancements for a clinical-stage pharmaceutical company: topline data readout from the APPROACH Phase 3 study of HLP003 for MDD on track for Q4 2026, and progression of the HLP004 program with Phase 2 monotherapy study for GAD expected to initiate in Q1 2027. The company also highlights a strategic shift in HLP004 development from adjunctive to monotherapy approach. These are significant operational and clinical milestones that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, though the disclosure is primarily an investor presentation summary rather than a discrete event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:47:03.998758+00:00","company_name":"Helus Pharma Inc.","ticker":"HELP","filing_date":"2026-10-21"}]}